Ionis Cuts Tryngolza Sales Forecast, Shares Hit Low
The drugmaker lowered its 2026 sales guidance for Tryngolza, citing a slower-than-expected launch for severe hypertriglyceridemia treatment.
Updated on Nov. 9, 2026 in Healthcare
Ionis Pharmaceuticals lowered its 2026 sales guidance for Tryngolza to approximately $50 million, down from $100 million to $110 million. Its shares fell to a 52-week low on Monday.
Why it matters
The company attributed the reduction to a severe hypertriglyceridemia launch progressing more gradually than expected, as health care professionals adapt to a new approach to patient care. The revision lowers near-term expectations for the drug.
Tryngolza's third-quarter U.S. net product sales were $9 million, against a revised 2026 guidance of about $50 million, down from $100 million to $110 million. Ionis affirmed its overall 2026 sales guidance of $875 million to $900 million, but the analysis of the Tryngolza revision is limited to the figures reported.
The players
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company that develops RNA-targeting medicines, including Tryngolza and Dawnzera.
The details
Ionis said the severe hypertriglyceridemia launch is progressing more gradually than expected, citing the need for health care professionals to adopt a new approach to patient care. The company still plans to reach positive cash flow by 2029, contingent on Tryngolza's uptake and pipeline successes.
Timeline
Third quarter 2026: Tryngolza generated $9 million in U.S. net product sales.
2026: Full-year Tryngolza sales guidance lowered to approximately $50 million.
Monday, November 9, 2026: Ionis shares fell to a 52-week low.
Market Landscape
The revision shows how a first-of-its-kind rare-disease therapy can move more slowly than initial guidance once it reaches clinicians who must change established care habits. Ionis's affirmed overall guidance alongside the cut to Tryngolza suggests the company is leaning on its other products, such as Dawnzera, to offset the weaker launch.
Investors tracking Ionis should weigh the lowered Tryngolza forecast against the company's affirmed overall 2026 sales guidance of $875 million to $900 million. The 2029 cash-flow target remains contingent on how quickly Tryngolza gains uptake.
The takeaway
A slower-than-expected rollout can signal that clinicians need time to adopt new treatment approaches, so near-term sales figures may understate a drug's longer-term potential. Tracking subsequent quarterly reports will show whether uptake accelerates as expected.
Further reading
For more on how new drug launches reshape care delivery, explore Healthcare coverage.
